EDUCATION
Emerging and Evolving Biomarkers: Recent Findings, Laboratory Considerations, and Clinical Implications
The extraordinary advancements made over the past several years in the clinical management of cancer have ushered in a new era of optimism for those afflicted with many cancer types. However, these advancements have also created a highly complex environment for healthcare providers and diagnostic laboratory personnel. With the range of clinically informative biomarkers, the types of tests to detect these biomarkers, and the resulting clinical implications constantly expanding and becoming more complex, it has become increasingly burdensome for healthcare professionals to keep pace.
This series will efficiently describe emerging and evolving biomarkers in a series of live webcasts that will be structured to provide a consistent framework in which to consider the application of new information on specific biomarkers.
Each live webcast will feature:
- 15-20 minutes of a scientific overview of recent and relevant research on the biomarker;
- 15-20 minutes covering the laboratory considerations for the testing approach to each biomarker;
- 15-20 minutes of discussion on the clinical implications of biomarker use.
After broadcast, each webinar will be posted on the AMPEDTM online Learning Management System as 1. A complete presentation with pre- and post-tests plus available continuing education credit and 2. A series of short learning modules that can be reviewed based on need and interest in the science, laboratory applications, and/or clinical implications of each marker. See below for links.
LEARNING OBJECTIVES
- Describe the biological principles that underlie the pathogenicity of each biomarker, including the cellular signaling pathways and cellular processes involved.
- Discuss the appropriate technical approaches and platforms for molecular diagnostic testing for each biomarker.
- Outline the strengths and limitations of described testing approaches.
- Apply biomarker information so as to order appropriate testing and interpret biomarker status results within a clinical context.
SCHEDULE
Webinar #1: MGMT: Updated Perspectives, Laboratory Considerations, and Clinical Implications
Speaker: Tejus Bale, MD, PhD
Recorded: Tuesday June 30th, 2020
Webinar #2: HRD Score: Updated Perspectives, Laboratory Considerations, and Clinical Implications
Speaker: Melinda Telli, MD
Date: Tuesday July 21st, 2020
Webinar #3: METex14: Updated Perspectives, Laboratory Considerations, and Clinical Implications
Speaker: Nikoletta Sidiropoulos, MD
Date: Tuesday September 29th, 2020
Webinar #4: NTRK: Updated Perspectives, Laboratory Considerations, and Clinical Implications
Speaker: Lynette M. Sholl, MD
Date: Tuesday December 8th, 2020
Webinar #5: ERBB2 (HER2) in Colorectal Cancer: Recent findings, laboratory considerations, and clinical implications
Speaker: Sinchita Roy-Chowdhuri, MD, PhD
Date: Thursday April 15th, 2021
Webinar #6: Myeloid Malignancy MRD: Recent Findings, Laboratory Considerations, and Clinical Implications
Speaker: David Wu, MD, PhD
Date: Tuesday June 29th, 2021
Webinar #7: KRAS: Recent Findings, Laboratory Considerations, and Clinical Implications
Speaker: Craig Mackinnon, MD, PhD
Date: Tuesday October 12th, 2021 at 2:00pm Eastern
Click on the links below to access the full webinar(s) or the 15-min microlearning module(s).
|
MICROLEARNING MODULES |
|||
|---|---|---|---|
|
BIOMARKERS
|
ALL
|
LABORATORY PROFESSIONALS
|
CLINICAL PRACTITIONERS
|
|
MGMT: |
Scientific Underpinnings |
Laboratory Considerations |
Clinical Implications |
|
HRD Score: |
Scientific Underpinnings |
Laboratory Considerations |
Clinical Implications |
|
METex14: |
Scientific Underpinnings |
Laboratory Considerations |
Clinical Implications |
|
NTRK: |
Scientific Underpinnings |
Laboratory Considerations |
Clinical Implications |
|
ERBB2 (HER2) in Colorectal Cancer: |
Scientific Underpinnings |
Laboratory Considerations |
Clinical Implications |
|
Myeloid Malignancy MRD: |
Scientific Underpinnings |
Laboratory Considerations |
Clinical Implications |
This webinar series on Emerging and Evolving Biomarkers (EEB) is planned and coordinated by the Emerging and Evolving Biomarkers Content Committee:
Kurtis D. Davies, PhD, Content Chair
University of Colorado, Anschutz Medical Campus
Anthony N. Snow, MD
University of Iowa Hospitals and Clinics, Carver College of Medicine
Lauren L. Ritterhouse, MD, PhD
Massachusetts General Hospital, Harvard Medical School
And supported by the AMP Training & Education Committee (Nathanael G. Bailey, MD, Chair)
This program has been supported through educational grant funding provided by Amgen, Bristol-Myers Squibb, and Loxo Oncology at Lilly (for further information concerning Lilly grant funding visit www.lillygrantoffice.com.) Supporting companies had no control over its content. No personally-identifiable information regarding you is provided to any grant supporters.
Instructions for Accessing Live and On-Demand Webinars from AMP (PDF)
.jpg)
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
